Allgens Medical Technology CO., LTD.was founded in 2004, and is a national high-tech enterprise focusing on the technology research and development, high-end manufacturing and market promotion of advanced biomaterials and implantable medical devices for regenerative medicine.
Allgens biomimetic mineralized collagen bone grafts have three national class III medical device registration certificates approved by NMPA, and have been approved by US FDA 510(k). With similar composition and microstructure to those of human bone, the products can be widely used for bone grafting in the fields of orthopedics, neurosurgery, stomatology, plastic surgery, and so on. The products have been used in more than one million cases, with remarkable bone defect repair and bone fusion effects. Many patients and their families obtained benefits from Allgens techniques and products.
|Earnings Per Share||0.89||0.68||0.34|
|R&D expenditure as a % of operating revenue||8.71%||13.34%||14.57%|
|Total Owners' Equity||651.68||563.76||451.7|
|Net Cash Flows-Operating||84.88||88.45||79.73|
|Net Cash Flows-Investing||-143.28||-206.5||-101.1|
|Net Cash Flows-Financing||4.23||107.23||94|
|Name||No. of Shares Held (mn)||% of Shares Held|
|Bioveda china RMB Investment limited||11.76||8.82%|
|Eric Gang Hu||9.49||7.12%|
|COWIN CHINA GROWTH FUNDI,L.P.||7.42||5.57|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.